

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

14 May 2024

Re-instatement to Official Quotation Imminent

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce that IBX will be re-instated to official quotation once a new Australian Director has been appointed.

Following the release of IBX's 2023 Annual Report, the ASX has indicated that it will re-instate IBX to official quotation once it is in compliance with s201A(2) of the Corporations Act, i.e. the requirement for a public company to have at least 3 directors, 2 of whom must reside in Australia. IBX is currently considering the appointment of an appropriate Australian resident Director.

— ENDS —

About Imagion Biosystems

Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company's lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems' MagSense® pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs.

For more information, visit <https://imaginationbiosystems.com/investor-hub/>

Authorisation & Additional information

This announcement was authorised by the Board of Imagion Biosystems Limited.

